TLR9 and prostate carcinoma: Activated TLR9, by CpG DNA in infection-induced cancers, or by tumor-derived DAMPs, induces NF-κB activation, resulting in immune cell infiltration, increased proliferation, and reduced apoptosis, as has been demonstrated in human prostate cancer [62].